NTRA

SEC source: 0001646382-25-000004 · form4-09172025_010943.xml · nonDerivative · entry 3

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Indirect · By spouse

Disclosed balance after: 25,000

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025.

SEC source: 0001646382-25-000004 · form4-09172025_010943.xml · nonDerivative · entry 2

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Indirect · By spouse

Disclosed balance after: 25,500

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.00 to $170.93 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-023825 · form4-09052025_090901.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,859

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.41 to $168.21 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-023825 · form4-09052025_090901.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 122,069

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.09 to $166.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-023825 · form4-09052025_090901.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 122,569

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.09 to $166.06 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-023826 · form4-09052025_090903.xml · nonDerivative · entry 3

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 158,514

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.41 to $168.28 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-023826 · form4-09052025_090903.xml · nonDerivative · entry 2

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 160,421

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.97 to $166.90 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-023826 · form4-09052025_090903.xml · nonDerivative · entry 1

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,893

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.93 to $165.7750 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-023477 · form4-09022025_090901.xml · nonDerivative · entry 4

Chapman Rowan E · CIK 0001786240 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,015

SEC source: 0001415889-25-022147 · form4-08152025_090801.xml · nonDerivative · entry 3

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,747

F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on October 22, 2021.

SEC source: 0001415889-25-022147 · form4-08152025_090801.xml · nonDerivative · entry 2

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,753

F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on October 22, 2021.

SEC source: 0001415889-25-022148 · form4-08152025_090803.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,859

F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on October 22, 2021.

SEC source: 0001415889-25-022148 · form4-08152025_090803.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,867

F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on October 22, 2021.

SEC source: 0001415889-25-022147 · form4-08152025_090801.xml · nonDerivative · entry 1

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,425

F1 · shares: On October 22, 2021, the Reporting Person was granted Restricted Stock Units ("RSUs") covering 10,000 shares of Common Stock which vest in tranches upon the achievement of certain milestones relating to a combination of the passage of time and certain business performance criteria. On August 12, 2025, the achievement of criteria was certified for the vesting of RSUs covering 1,675 shares of Common Stock.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock..

SEC source: 0001415889-25-022148 · form4-08152025_090803.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,734

F1 · shares: On October 22, 2021, the Reporting Person was granted Restricted Stock Units ("RSUs") covering 10,000 shares of Common Stock which vest in tranches upon the achievement of certain milestones relating to a combination of the passage of time and certain business performance criteria. On August 12, 2025, the achievement of criteria was certified for the vesting of RSUs covering 1,675 shares of Common Stock.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 16

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 34,282

F8 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F10 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 15

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 34,302

F8 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F17 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.12 to $156.08 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 14

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 34,912

F8 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F16 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.94 to $154.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 13

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 35,182

F8 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F15 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.24 to $152.56 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 12

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 35,362

F8 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F14 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.92 to $151.50 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 11

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 35,662

F8 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F13 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.50 to $149.89 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 10

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 34,282

F8 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F12 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.40 to $156.32 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 9

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 34,921

F8 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.25 to $155.14 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 8

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 35,112

F8 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F10 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 7

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 35,312

F8 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.49 to $151.40 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 6

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 242,252

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.44 to $164.59 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 5

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 242,452

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.29 to $164.22 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 4

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 243,252

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.22 to $163.21 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 3

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 244,282

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.28 to $160.01 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 2

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 244,921

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.26 to $159.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-021524 · form4-08122025_090801.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 245,222

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.36 to $156.45 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-021139 · form4-08052025_090801.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,059

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

SEC source: 0001415889-25-021139 · form4-08052025_090801.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,159

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.96 to $133.80 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-021139 · form4-08052025_090801.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,485

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.9350 to $132.78 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-021141 · form4-08052025_090805.xml · nonDerivative · entry 2

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 163,593

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.9350 to $133.80 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-021141 · form4-08052025_090805.xml · nonDerivative · entry 1

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 166,590

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.8850 to $132.87 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-021140 · form4-08052025_090803.xml · nonDerivative · entry 2

Marcus Gail Boxer · CIK 0001702176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,763

F1 · shares: .The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.2647 to $134.20 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-021140 · form4-08052025_090803.xml · nonDerivative · entry 1

Marcus Gail Boxer · CIK 0001702176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,946

F1 · shares: .The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.23 to $133.0664 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-020666 · form4-07302025_090701.xml · nonDerivative · entry 4

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,430

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.00 to $138.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-020666 · form4-07302025_090701.xml · nonDerivative · entry 3

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,708

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.00 to $137.70 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-020666 · form4-07302025_090701.xml · nonDerivative · entry 2

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,908

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.83 to $136.39 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-020662 · form4-07302025_090703.xml · nonDerivative · entry 1

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,750

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023 and January 26, 2024.

SEC source: 0001415889-25-020663 · form4-07302025_090705.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,059

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023 and January 26, 2024.

SEC source: 0001415889-25-020667 · form4-07302025_090704.xml · nonDerivative · entry 1

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 169,400

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023 and January 26, 2024.

SEC source: 0001415889-25-020666 · form4-07302025_090701.xml · nonDerivative · entry 1

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,475

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023 and January 26, 2024.

SEC source: 0001415889-25-020665 · form4-07302025_090710.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 245,322

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023 and January 26, 2024.

SEC source: 0001415889-25-020664 · form4-07302025_090707.xml · nonDerivative · entry 1

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,360,852

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024.

SEC source: 0001415889-25-020661 · form4-07302025_090701.xml · nonDerivative · entry 1

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 202,164

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023 and January 26, 2024.

SEC source: 0001415889-25-020515 · form4-07292025_090703.xml · nonDerivative · entry 1

Bertagnolli Monica · CIK 0001761030 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,128

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $16,875 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-25-020518 · form4-07292025_090710.xml · nonDerivative · entry 1

ROSENMAN HERM · CIK 0001230057 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,629

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in lieu of quarterly retainer fees of $23,750 for service on the Issuer's Board of Directors. The RSUs were fully vested at the time of issuance.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.